california semaglutide ban FDA moves to remove GLP-1 medications from 503B Bulks List Despite FDA ruling, compounded GLP-1s

Stacking BPC 157 With Other Peptides for Tendon Research In the world of advanced peptide research, investigators rarely look at a single compound in a vacuum

Why the boring, legal basics win

Regulatory Status BPC-157 is not approved by Health Canada for human use

Injection site reactions occur in roughly 1.4% to 2.4% of patients using subcutaneous semaglutide, according to clinical trial data

In normal human physiology, GLP-1 and GIP are released by the gastrointestinal tract (enteroendocrine L cells in the small intestine and colon and enteroendocrine K cells respectively) in response to nutrient intake and have half-lives of 1 to 3 min [36]

One of our licensed providers will briefly review your wellness goals and health history